Effective Cancer Therapy with Alpha-Particle Emitter At-211

Researchers at Hannover Medical School in Germany have successfully used the alpha-particle emitter At-211 to effectively eradicate cancer in a mouse model of genetically modified sodium/iodide symporter (NIS)-expressing tumors. By exploiting the NIS gene, the team was able to deliver the radioactive At-211 directly to the tumor cells, causing complete primary tumor eradication in all cases within three months. This groundbreaking research opens up new possibilities for cancer treatment, particularly for cases where traditional therapies have failed.

Key Takeaways:

• The alpha-particle emitter At-211 was used to effectively eradicate cancer in a mouse model of genetically modified NIS-expressing tumors.
• The researchers achieved complete primary tumor eradication in 100% of cases (n=25) within three months.
• The survival rates of the K1-NIS/At-211 group were 96% after six months and 60% after one year, in contrast to control groups with maximum survival of 40 days.
• The study indicates that At-211 represents a promising substrate for NIS-mediated therapy of various cancers.
• The research was conducted using a mouse model of rapidly growing solid tumors established from a papillary thyroid carcinoma cell line genetically modified to express NIS.
• The study also measured body weight, blood counts, and side effects, with no significant adverse effects observed.

Statistics:

• 100% of mice in the K1-NIS/At-211 group experienced complete primary tumor eradication within three months.
• 96% survival rate after six months in the K1-NIS/At-211 group.
• 60% survival rate after one year in the K1-NIS/At-211 group.
• Maximum survival time in control groups was 40 days.

Sources:

• Petrich et al., Clinical Cancer Research (2006); 12(4):1342-1348.